ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALZN vs JNJ // RSI-14 & 200D SMA MOMENTUM

Alzamend Neuro Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ALZN 0 — JNJ 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALZN VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALZN JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.97% — TIE /fcf-yield <GO>
Operating Margin — 34.70% — TIE /operating-margins <GO>
Net Profit Margin — 28.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 6.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 8/9 -7.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 37.8 62.1 -24.32 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.9M $662.49B -$662.49B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALZN REV JNJ REV ALZN GROSS % JNJ GROSS % ALZN FCF JNJ FCF
FY 2025 $0 $94.19B — 67.9% -$8.1M $19.70B
FY 2024 $0 $88.82B — 69.1% -$6.6M $19.84B
FY 2023 $0 $85.16B — — -$8.3M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALZN // BETA —
JNJ // BETA 1.08